Crinetics Pharmaceuticals (CRNX) Equity Average (2018 - 2026)

Crinetics Pharmaceuticals has reported Equity Average for 9 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 11.87% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (down 11.87% YoY), and the FY2025 full-year result was $1.2 billion, up 24.3% from the prior year.
• Equity Average for Q1 2026 stood at $1.1 billion, up from $1.0 billion in the prior quarter.
• The five-year high for Equity Average was $1.3 billion in Q1 2025, with the low at $267.2 million in Q2 2023.
• Average Equity Average over 5 years is $714.0 million, with a median of $707.0 million recorded in 2024.
• Year-over-year, Equity Average fell 22.46% in 2023 and soared 219.15% in 2024.
• Tracing CRNX's Equity Average over 5 years: stood at $333.8 million in 2022, then jumped by 62.78% to $543.4 million in 2023, then jumped by 98.53% to $1.1 billion in 2024, then declined by 4.33% to $1.0 billion in 2025, then climbed by 10.1% to $1.1 billion in 2026.
• The last three Equity Average figures came in at $1.1 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison